EU life sciences investment gathers pace as Sofinnova closes €725m fund and new rounds are announced

Investor appetite for European life sciences was underlined this week as a €725m crossover closed above target and two biotechnology companies announced new funding

You need to be a subscriber to read this article.
Click here to find out more.

Sofinnova Partners has announced the final close of Sofinnova Crossover II at €725m ($815m), exceeding its original target.

The fund will back late-stage companies through clinical development, global expansion and commercialisation.

It will focus mainly on European clinical-stage biopharma and medtech firms, with selective investments in the US and other markets.

Sofinnova expects to invest in around 15 companies and has already backed Hemab Therapeutics, CellCentric and Neurent Medical.

Antoine Papiernik, Chair and Managing Partner of Sofinnova Partners, said the fund’s scale “reflects both the maturity of the European life sciences ecosystem and the rising demand for capital that can help companies to reach global markets.” 

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

You may also like